Cure My Disease

Don't miss your cure!

 Log in / Sign up

World's largest registry launches for deadly heart tumor

NCT ID NCT06715579

Knowledge-focused Sponsor: Immune Oncology Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This international registry will gather data from 500 people diagnosed with cardiac angiosarcoma, a rare and aggressive heart cancer. Researchers aim to identify risk factors and evaluate which treatments—like surgery, chemo, or immunotherapy—work best. The goal is to create evidence-based guidelines to improve survival and care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help doctors identify better treatments and create standard care guidelines for this rare heart cancer.
What could go wrong
This is an observational registry, not a treatment trial. It collects existing data and won't directly test new therapies, so improvements may take years to emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients diagnosed with Cardiac Angiosarcoma

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma. * Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035. * Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations. * Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes. * Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry. * Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis. * Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts. Exclusion Criteria: * Patients who decline to provide informed consent. * Cases where cardiac involvement is secondary to another primary malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac angiosarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angiosarcoma heart sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac angiosarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yeolyan Hematology and Oncology Center

    RECRUITING

    Yerevan, 0014, Armenia